The pharma‑grade water blueprint: Double‑pass RO, CEDI, and hot WFI loops built for audits

For pharma utilities teams, water quality is a test you either pass or fail. USP Purified Water must hit ≤1.3 μS/cm at 25 °C conductivity and ≤500 ppb TOC (total organic carbon), with microbial counts below 100 CFU/mL, according to www.pharmaceuticalprocessingworld.com.

Water for Injection goes further: essentially sterile, endotoxin <0.25 EU/mL (endotoxin units per mL), historically via distillation only, per www.pharmaceuticalprocessingworld.com. Recent WHO/EP updates permit validated non‑distillation processes for WFI (www.who.int), but this design assumes distillation for compliance.

The incoming feed must meet potable standards and is preferably chlorinated municipal water. Pre‑treatment must remove turbidity, hardness, chlorine, and organics to protect membranes and resins (odoo.durpro.com; www.pharmaceuticalprocessingworld.com).

Compendial targets and design stance

USP 〈1231〉 and WHO recommend PW ≤1.3 µS/cm and TOC ≤500 ppb (www.pharmaceuticalprocessingworld.com). WFI quality remains anchored to endotoxin <0.25 EU/mL and sterility, with this design opting for distillation despite WHO/EP allowances for validated alternatives (www.who.int).

The end‑to‑end system is sized for steady compliance and sanitization: removal processes upfront, double‑pass RO (reverse osmosis) plus CEDI (continuous electrodeionization) for ionic polishing, and a still for WFI.

Pre‑treatment: filtration, softening, carbon

Chlorinated potable water first passes through multimedia filters (sand/anthracite) to cut turbidity to <1 NTU, a measure of clarity (patents.google.com). Plants commonly specify dual‑media beds using silica sand such as dual media sand filtration.

To build multi‑layer beds with long service life, many designs incorporate anthracite media; options like anthracite filtration media support that approach.

A two‑bed water softener (strong acid cation exchange) removes hardness (Ca/Mg) to protect downstream RO. Design targets are outlet hardness <1–2 ppm as CaCO₃, with typical resin capacity around ~25,000–30,000 grains/ft³ (e.g., 20–30×10³ grains) (patents.google.com).

Commercial softening systems are paired with high‑purity ion‑exchange resins to achieve those capacities consistently.

Downstream, a granular activated carbon (GAC) filter removes residual chlorine and organics. A well‑sized carbon stage typically drops chlorine from ~0.5–2 ppm in feed to <0.02 ppm (often undetectable) (patents.google.com). Systems often add high‑intensity UV as a backup dechlorination step.

Plants deploy GAC through activated carbon filtration, and many incorporate UV barriers using ultraviolet disinfection as that non‑chemical safety net.

A 1–5 μm final particulate barrier—bag or cartridge—polishes feed to the RO. Pharmaceutical skids frequently mount these in 316L housings; sanitary options like stainless steel cartridge housings and high‑surface‑area cartridge filters fit this service.

Primary purification: double‑pass RO plus CEDI

The core train is double‑pass RO (DPRO) followed by CEDI. First‑pass RO, running at ~10–15 bar, removes ~98–99% of salts and yields permeate at typically 70–80% of feed; the second pass further polishes, with overall recovery ~50–70% (for example, 70% then 85% ≈ ~60% net) (www.eurowater.com).

DPRO routinely produces <1–5 µS/cm water (hundreds of kΩ‑cm resistivity); one implementation ran 3.0 m³/h DPRO to <5 µS/cm (www.eurowater.com). Many facilities specify packaged brackish‑water RO skids for this duty.

Membrane arrays are often selected from established lines; for instance, plants frequently reference Filmtec RO membranes for pharmaceutical service.

To control biofilm, the RO system is designed for thermal or chemical sanitization (hot water up to ~80°C) (www.eurowater.com).

RO permeate feeds CEDI, which uses electric current and ion‑exchange membranes to drive further ionic removal, delivering high‑resistivity water (~18 MΩ·cm) and additional organic/pyrogen reduction (www.pharmaceuticalprocessingworld.com). A vacuum degasser is often installed upstream to strip dissolved CO₂ that would otherwise depress conductivity.

Product after CEDI typically reads <1 µS/cm (≥1 MΩ·cm), and with effective upstream GAC and UV, TOC is usually well below 500 ppb. Online sensors track conductivity, TOC, and temperature continuously, while periodic hot‑water CIP loops (for example, circulating 80°C water weekly) and no dead‑legs keep biofilm in check.

Pharma utilities teams commonly deploy packaged EDI units to meet these resistivity targets while avoiding chemical regeneration.

Key metrics for this stage: output conductivity (<5 µS/cm), TOC (<500 ppb, often <50 ppb), and bioburden (<100 CFU/mL), which readily align with USP expectations (www.pharmaceuticalprocessingworld.com; www.eurowater.com).

WFI distillation unit and hot loop

For WFI, a final distillation unit takes CEDI‑grade feed. Multi‑effect evaporators (falling‑film or natural‑circulation) are standard; a 3‑effect still can yield ~70–80% of its feed as condensate, with more effects or mechanical vapor recompression boosting efficiency.

Distillation “electronically strips non‑volatiles” (salts, endotoxins, ammonia, silica), producing condensate with TDS often <1–2 ppm (patents.google.com). It also sterilizes the stream outright.

The distillate storage tank and loop are typically held at >70°C (often ~80°C) continuously for self‑sanitization (gmpua.com). This high‑temperature loop eliminates the need for chemical sanitizers (gmpua.com).

Outputs: ultra‑pure water (resistivity ~18 MΩ·cm), no detectable chlorine or solids, and essentially zero CFU. By pharmacopeia, WFI must meet endotoxin <0.25 EU/mL and pass sterility tests. While newer EP/WHO guidance allows validated RO+polish instead of distillation (www.who.int), a still remains aligned with legacy FDA/USP practice.

Design notes: 316L stainless steel for wetted surfaces, sanitize the still with clean steam (e.g., 80°C steam) followed by hot flush, and provide venting through a 0.2 μm sterile filter. Distillate pumps and heat exchangers should be sanitary and CIP‑compatible.

Storage tanks and distribution loops

PW and WFI are stored in separate USP‑grade 316L tanks (electropolished, Ra ≤0.8 µm) (gmpua.com). Volume is sized for anticipated peak demand plus margin—e.g., 1–2 days of use.

Tanks use sanitary hygienic fittings (tri‑clamp), capacitive level sensors, and hot‑water spray balls for CIP. Supporting hardware—vents, valves, and regulators—typically falls under hygienic ancillaries, the kind of kit grouped as water treatment ancillaries.

Each water grade circulates in a closed loop driven by 316L centrifugal pumps, with flow sized for turbulence (≥1.0–1.5 m/s) to “chaotically rinse” pipe walls and deter biofilms (gmpua.com).

Distribution design eliminates dead legs: branches only at flow points and strict adherence to the 6D rule for unswept pipe (gmpua.com). Many plants run PW loops heated at 40–50°C for microbial control, while WFI loops operate hot at ≈80°C (gmpua.com).

If any process draw points must run ambient, those lines return to the hot loop after use. Distribution pumps run 24/7 or on a qualified schedule. Automated CIP—e.g., hot‑water flush at 70–80°C for 15–30 min weekly or monthly—tracks to microbial trending.

Materials and finish are non‑negotiable: 316L stainless throughout with traceability, full‑penetration orbital welds, continuously welded joints (no gaskets), and surface finish ≤0.8 µm Ra (electropolished after fabrication) (gmpua.com). Sanitary valves and non‑leaching in‑line conductivity sensors are standard. Return points are sampled to verify <100 CFU/mL (USP), and mature systems often run <10 CFU/mL.

Performance monitoring and alert levels

Continuous monitoring covers conductivity (or resistivity), temperature, and TOC. Typical control targets: PW loop resistivity >1 MΩ·cm (≈1 µS/cm at 25°C) and WFI at essentially its maximum (~18 MΩ·cm, ~0.06 µS/cm). Alert/action levels align to USP—for example, alert if PW >1.3 µS/cm, action at 0.7–0.8 MΩ·cm deficiency (www.pharmaceuticalprocessingworld.com).

Microbial control is verified with frequent sampling: nightly handholds and weekly loop samples, aiming to routinely see <10 CFU/mL. Seven‑day RTU trending charts provide actionable data; historically, most quality excursions are microbial (www.pharmaceuticalprocessingworld.com), making loop temperature and sanitization the key levers.

Outcomes, case evidence, and design levers

A well‑designed RO/CDI plant has demonstrated 3 m³/h at <5 µS/cm (90+% typical rejection) (www.eurowater.com). Proper sanitization keeps bioburden typically <5 CFU/mL in the loop.

These performance claims track with industry best practice on pre‑treatment and RO protection (odoo.durpro.com) and with documented RO yields and hot‑water sanitization strategies (www.eurowater.com).

Design decisions should be data‑driven: raise loop temperature or sanitize more often if CFU trends rise; ensure recovery rates (≥50%) to manage utility costs; and size storage for production plus safety. GMP guidance stresses loop layout, materials, and welding quality as the foundation of microbial control (gmpua.com).